Azaindazole Compounds As CCR1 Receptor Antagonists

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of...

Full description

Saved in:
Bibliographic Details
Main Authors TAN ZHULIN, MAO CAN, LIU PINGRONG, HARCKEN CHRISTIAN, COOK BRIAN NICHOLAS, LORD JOHN, RAZAVI HOSSEIN, LEE THOMAS WAI-HO, SONG JINHUA J, KUZMICH DANIEL, REEVES JONATHAN TIMOTHY, RAUDENBUSH BRIAN CHRISTOPHER, NEU JOCHEN, FANDRICK DANIEL ROBERT, SWINAMER ALAN DAVID, DISALVO DARREN
Format Patent
LanguageEnglish
Published 09.02.2012
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
Bibliography:Application Number: US201113273509